Literature DB >> 9356493

Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.

G Tortora1, R Caputo, V Damiano, R Bianco, S Pepe, A R Bianco, Z Jiang, S Agrawal, F Ciardiello.   

Abstract

Protein kinase A type I plays a key role in neoplastic transformation, conveying mitogenic signals of different growth factors and oncogenes. Inhibition of protein kinase A type I by antisense oligonucleotides targeting its RIalpha regulatory subunit results in cancer cell growth inhibition in vitro and in vivo. A novel mixed backbone oligonucleotide HYB 190 and its mismatched control HYB 239 were tested on soft agar growth of several human cancer cell types. HYB 190 demonstrated a dose-dependent inhibition of colony formation in all cell lines whereas the HYB 239 at the same doses caused a modest or no growth inhibition. A noninhibitory dose of each mixed backbone oligonucleotide was used in OVCAR-3 ovarian and GEO colon cancer cells to study whether any cooperative effect may occur between the antisense and a series of cytotoxic drugs acting by different mechanisms. Treatment with HYB 190 resulted in an additive growth inhibitory effect with several cytotoxic drugs when measured by soft agar colony formation. A synergistic growth inhibition, which correlated with increased apoptosis, was observed when HYB 190 was added to cancer cells treated with taxanes, platinum-based compounds, and topoisomerase II selective drugs. This synergistic effect was also observed in breast cancer cells and was obtained with other related drugs such as docetaxel and carboplatin. Combination of HYB 190 and paclitaxel resulted in an accumulation of cells in late S-G2 phases of cell cycle and marked induction of apoptosis. A cooperative effect of HYB 190 and paclitaxel was also obtained in vivo in nude mice bearing human GEO colon cancer xenografts. These results are the first report of a cooperative growth inhibitory effect obtained in a variety of human cancer cell lines by antisense mixed backbone oligonucleotide targeting protein kinase A type I-mediated mitogenic signals and specific cytotoxic drugs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356493      PMCID: PMC25047          DOI: 10.1073/pnas.94.23.12586

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

Review 1.  Antisense-protein kinase A: a single-gene-based therapeutic approach.

Authors:  Y S Cho-Chung; M Nesterova; A Kondrashin; K Noguchi; R Srivastava; S Pepe
Journal:  Antisense Nucleic Acid Drug Dev       Date:  1997-06

Review 2.  In vivo studies with antisense oligonucleotides.

Authors:  S Akhtar; S Agrawal
Journal:  Trends Pharmacol Sci       Date:  1997-01       Impact factor: 14.819

3.  8-Chloro-cAMP inhibits transforming growth factor alpha transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation.

Authors:  F Ciardiello; G Tortora; N Kim; T Clair; S Ally; D S Salomon; Y S Cho-Chung
Journal:  J Biol Chem       Date:  1990-01-15       Impact factor: 5.157

4.  Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cyclic adenosine monophosphate.

Authors:  S Ally; T Clair; D Katsaros; G Tortora; H Yokozaki; R A Finch; T L Avery; Y S Cho-Chung
Journal:  Cancer Res       Date:  1989-10-15       Impact factor: 12.701

5.  The RIalpha subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor.

Authors:  G Tortora; V Damiano; C Bianco; G Baldassarre; A R Bianco; L Lanfrancone; P G Pelicci; F Ciardiello
Journal:  Oncogene       Date:  1997-02-27       Impact factor: 9.867

6.  Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.

Authors:  T Skorski; M Nieborowska-Skorska; P Wlodarski; D Perrotti; G Hoser; J Kawiak; M Majewski; L Christensen; R V Iozzo; B Calabretta
Journal:  J Natl Cancer Inst       Date:  1997-01-15       Impact factor: 13.506

7.  8-chloro-cAMP enhances the growth inhibitory effect of cytotoxic drugs in human colon cancer cells.

Authors:  G Diisernia; F Ciardiello; C Sandomenico; S Pepe; A Bianco; G Tortora
Journal:  Int J Oncol       Date:  1996-12       Impact factor: 5.650

8.  Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice.

Authors:  S Agrawal; J Temsamani; J Y Tang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-01       Impact factor: 11.205

9.  In vivo treatment of human leukemia in a scid mouse model with c-myb antisense oligodeoxynucleotides.

Authors:  M Z Ratajczak; J A Kant; S M Luger; N Hijiya; J Zhang; G Zon; A M Gewirtz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

10.  An antisense oligodeoxynucleotide that depletes RI alpha subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells.

Authors:  H Yokozaki; A Budillon; G Tortora; S Meissner; S L Beaucage; K Miki; Y S Cho-Chung
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

View more
  5 in total

1.  A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancers.

Authors:  Sanjay Goel; Kavita Desai; Manuel Macapinlac; Scott Wadler; Gary Goldberg; Abbie Fields; Mark Einstein; Fabio Volterra; Benny Wong; Russell Martin; Sridhar Mani
Journal:  Invest New Drugs       Date:  2006-03       Impact factor: 3.850

2.  Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family.

Authors:  D Jean; M Bar-Eli
Journal:  Mol Cell Biochem       Date:  2000-09       Impact factor: 3.396

3.  PKA knockdown enhances cell killing in response to radiation and androgen deprivation.

Authors:  Harvey H Hensley; Jean-Michel Hannoun-Levi; Paul Hachem; Zhaomei Mu; Radka Stoyanova; Li-Yan Khor; Sudhir Agrawal; Alan Pollack
Journal:  Int J Cancer       Date:  2010-10-19       Impact factor: 7.396

4.  NO-Evoked macrophage apoptosis is attenuated by cAMP-induced gene expression.

Authors:  A von Knethen; F Brockhaus; I Kleiter; B Brüne
Journal:  Mol Med       Date:  1999-10       Impact factor: 6.354

5.  Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.

Authors:  T Troiani; L Vecchione; E Martinelli; A Capasso; S Costantino; L P Ciuffreda; F Morgillo; D Vitagliano; E D'Aiuto; R De Palma; S Tejpar; E Van Cutsem; M De Lorenzi; M Caraglia; L Berrino; F Ciardiello
Journal:  Br J Cancer       Date:  2012-05-08       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.